377 related articles for article (PubMed ID: 19125776)
1. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Idris I; Donnelly R
Diabetes Obes Metab; 2009 Feb; 11(2):79-88. PubMed ID: 19125776
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Chen LH; Leung PS
Diabetes Obes Metab; 2013 May; 15(5):392-402. PubMed ID: 23331516
[TBL] [Abstract][Full Text] [Related]
5. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Vallon V
Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
[TBL] [Abstract][Full Text] [Related]
6. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
7. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
Jabbour SA; Goldstein BJ
Int J Clin Pract; 2008 Aug; 62(8):1279-84. PubMed ID: 18705823
[TBL] [Abstract][Full Text] [Related]
8. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
9. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Mauricio D
Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522
[TBL] [Abstract][Full Text] [Related]
10. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
Cuypers J; Mathieu C; Benhalima K
Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
[TBL] [Abstract][Full Text] [Related]
11. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Chao EC
Discov Med; 2011 Mar; 11(58):255-63. PubMed ID: 21447284
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
[TBL] [Abstract][Full Text] [Related]
13. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
14. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Rizos EC; Elisaf MS
Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.
Deshmukh AB; Patel MC; Mishra B
Ren Fail; 2013; 35(4):566-72. PubMed ID: 23438184
[TBL] [Abstract][Full Text] [Related]
18. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
Wan HX; Shen JK
Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
[TBL] [Abstract][Full Text] [Related]
19. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Freeman JS
Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
[TBL] [Abstract][Full Text] [Related]
20. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Kim GW; Chung SH
Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]